$2.20
-0.12-5.17%
At close: -
$2.19
-0.01-0.45%
After Hours: 5:17 PM EDT
Comments
Loading...
Cyclacel Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:CYCC | Benzinga
Cyclacel Pharmaceuticals Inc has a consensus price target of $9.5 based on the ratings of 3 analysts. The high is $11 issued by Roth MKM on May 3, 2024. The low is $8 issued by Oppenheimer on May 25, 2023. The 3 most-recent analyst ratings were released by Roth MKM, Roth MKM, and Oppenheimer on May 3, 2024, December 19, 2023, and May 25, 2023, respectively. With an average price target of $13.33 between Roth MKM, Roth MKM, and Oppenheimer, there's an implied 508.83% upside for Cyclacel Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Roth MKM
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Cyclacel Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/03/2024 | Buy Now | 402.28% | Roth MKM | Jonathan Aschoff34% | $21 → $11 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | — | Brookline Capital | Kemp Dolliver27% | — | Downgrade | Buy → Hold | Get Alert |
| 12/19/2023 | Buy Now | 858.9% | Roth MKM | Jonathan Aschoff34% | $16 → $21 | Maintains | Buy | Get Alert |
| 05/25/2023 | Buy Now | 265.3% | Oppenheimer | Jeff Jones33% | → $8 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | 265.3% | Oppenheimer | Jeff Jones33% | $10 → $8 | Maintains | Outperform | Get Alert |
| 07/18/2022 | Buy Now | 676.26% | Oppenheimer | Jeff Jones33% | → $17 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Cyclacel Pharmaceuticals (CYCC) stock?
The latest price target for Cyclacel Pharmaceuticals (NASDAQ:CYCC) was reported by Roth MKM on May 3, 2024. The analyst firm set a price target for $11.00 expecting CYCC to rise to within 12 months (a possible 402.28% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cyclacel Pharmaceuticals (CYCC)?
The latest analyst rating for Cyclacel Pharmaceuticals (NASDAQ:CYCC) was provided by Roth MKM, and Cyclacel Pharmaceuticals maintained their buy rating.
When was the last upgrade for Cyclacel Pharmaceuticals (CYCC)?
There is no last upgrade for Cyclacel Pharmaceuticals
When was the last downgrade for Cyclacel Pharmaceuticals (CYCC)?
The last downgrade for Cyclacel Pharmaceuticals Inc happened on December 19, 2023 when Brookline Capital changed their price target from N/A to N/A for Cyclacel Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Cyclacel Pharmaceuticals (CYCC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclacel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclacel Pharmaceuticals was filed on May 3, 2024 so you should expect the next rating to be made available sometime around May 3, 2025.
Is the Analyst Rating Cyclacel Pharmaceuticals (CYCC) correct?
While ratings are subjective and will change, the latest Cyclacel Pharmaceuticals (CYCC) rating was a maintained with a price target of $21.00 to $11.00. The current price Cyclacel Pharmaceuticals (CYCC) is trading at is $2.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
